Daclatasvir Single Patient IND AI444203

Expanded-access single named patient guidance document for the use of BMS 790052 in combination with sofosbuvir for the treatment of a patient with recurrent hepatitis C virus infection

The purpose of this program is to provide access to daclatasvir to patients who are infected with chronic hepatitis C virus (HCV).

Are you Eligible? (Inclusion Criteria)

Patients with chronic HCV infection needing urgent treatment with sofosbuvir and daclatasvir, who are not eligibile for standard treatment with FDA approved drugs, or other other studies.

Specialty Area(s)

Trial Location

NYP/Columbia
New York, NY 10032
United States